bendazac
Small moleculeexperimental
Clinical trial activity
0 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Mechanism of action
- Xanthine dehydrogenaseINHIBITOR
XDH inhibitor
Bendazac has anti-inflammatory, antinecrotic, choleretic and antilipidaemic properties, but its principal effect is to inhibit the denaturation of proteins. It protects lens proteins from denaturation, aggregation and precipitation in the medical treatment of senile cataract. Inhibits xanthine oxidase (XO) but not xanthine dehydrogenase (XDH). The oxidation of -SH groups near the active center, during the conversion of XDH to reversible XO, produces a conformational modification which allows bendazac to bind to reversible XO inhibiting the enzyme activity. The lysine salt is better absorbed than the parent compound after oral administration.
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)COc1nn(Cc2ccccc2)c2ccccc12- Mol. weight
- 282.3 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1089221 ↗
- ChEMBLCHEMBL600325 ↗
- ChEMBLCHEMBL1089222 ↗
Also known as
- 1-benzylindazole-3-oxyacetic acid
- af 1934
- af-1934
- af-1934
- af-1934
- bendalina
- bendaline
- bendazac
- bendazac
- bendazac
- bendazac
- bendazac
- bendazac
- bendazac
- bendazac lysine
- bendazac lysine
- bendazac lysine
- bendazac lysine
- bendazac lysine
- bendazac lysine salt
- bendazolic acid
- bendazolic acid
- bendazolic acid, sodium salt
- bindazac
- bindazac
- bindazac
- bindazac